CN101918004A - 克拉维酸的药物制剂 - Google Patents

克拉维酸的药物制剂 Download PDF

Info

Publication number
CN101918004A
CN101918004A CN2008801224638A CN200880122463A CN101918004A CN 101918004 A CN101918004 A CN 101918004A CN 2008801224638 A CN2008801224638 A CN 2008801224638A CN 200880122463 A CN200880122463 A CN 200880122463A CN 101918004 A CN101918004 A CN 101918004A
Authority
CN
China
Prior art keywords
clavulanic acid
clavulanate
pharmaceutical composition
mixture
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801224638A
Other languages
English (en)
Chinese (zh)
Inventor
李永福
金德中
安昌浩
爱德华·卡尔·朔尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opus Genetics Inc
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of CN101918004A publication Critical patent/CN101918004A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2008801224638A 2007-10-26 2008-10-24 克拉维酸的药物制剂 Pending CN101918004A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99607907P 2007-10-26 2007-10-26
US60/996,079 2007-10-26
PCT/US2008/012126 WO2009055038A1 (en) 2007-10-26 2008-10-24 Pharmaceutical formulation of clavulanic acid

Publications (1)

Publication Number Publication Date
CN101918004A true CN101918004A (zh) 2010-12-15

Family

ID=40579869

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801224638A Pending CN101918004A (zh) 2007-10-26 2008-10-24 克拉维酸的药物制剂

Country Status (11)

Country Link
US (1) US20090270358A1 (enExample)
EP (1) EP2214680A4 (enExample)
JP (1) JP2011500811A (enExample)
KR (1) KR20100101574A (enExample)
CN (1) CN101918004A (enExample)
AU (1) AU2008317315A1 (enExample)
BR (1) BRPI0818702A2 (enExample)
CA (1) CA2703224A1 (enExample)
IL (1) IL205313A0 (enExample)
MX (1) MX2010004556A (enExample)
WO (1) WO2009055038A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102058584A (zh) * 2010-12-30 2011-05-18 石药集团河北中润制药有限公司 克拉维酸钾/微晶纤维素组合物的制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255099A1 (en) * 2007-10-26 2010-10-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
KR101628095B1 (ko) 2010-10-18 2016-06-08 현대자동차 주식회사 저압 ｅｇｒ시스템 제어장치 및 방법
US9751957B2 (en) 2012-02-15 2017-09-05 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
KR102112119B1 (ko) 2012-10-22 2020-05-19 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
WO2015153984A2 (en) 2014-04-04 2015-10-08 Pharmaquest International Center, LLC Disintegrating monolithic modified release tablets containing quadri-layer extended release granules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014739A1 (en) * 1999-08-16 2004-01-22 Koppel Gary A. Neurotherapeutic clavulanate composition and method
US20060093680A1 (en) * 2003-02-12 2006-05-04 Vlasta Humar Coated particles and pharmaceutical dosage forms
US20060122159A1 (en) * 2004-08-13 2006-06-08 Huq Abu S Pharmaceutical formulation
US20070249523A1 (en) * 2001-02-14 2007-10-25 Koppel Gary A Neurotherapeutic composition and method therefor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9405856D0 (en) * 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
GB9518917D0 (en) * 1995-09-15 1995-11-15 Smithkline Beecham Plc Compounds
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US7166626B2 (en) 2001-06-18 2007-01-23 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
CA2644911A1 (en) * 2006-03-24 2007-10-04 Panacea Biotec Ltd. Antibiotic compositions of modified release and process of production thereof
US20100255099A1 (en) * 2007-10-26 2010-10-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014739A1 (en) * 1999-08-16 2004-01-22 Koppel Gary A. Neurotherapeutic clavulanate composition and method
US20070249523A1 (en) * 2001-02-14 2007-10-25 Koppel Gary A Neurotherapeutic composition and method therefor
US20060093680A1 (en) * 2003-02-12 2006-05-04 Vlasta Humar Coated particles and pharmaceutical dosage forms
US20060122159A1 (en) * 2004-08-13 2006-06-08 Huq Abu S Pharmaceutical formulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102058584A (zh) * 2010-12-30 2011-05-18 石药集团河北中润制药有限公司 克拉维酸钾/微晶纤维素组合物的制备方法

Also Published As

Publication number Publication date
JP2011500811A (ja) 2011-01-06
IL205313A0 (en) 2010-12-30
EP2214680A1 (en) 2010-08-11
WO2009055038A1 (en) 2009-04-30
AU2008317315A1 (en) 2009-04-30
MX2010004556A (es) 2010-07-01
EP2214680A4 (en) 2010-12-29
BRPI0818702A2 (pt) 2015-04-22
CA2703224A1 (en) 2009-04-30
KR20100101574A (ko) 2010-09-17
US20090270358A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
CN101918004A (zh) 克拉维酸的药物制剂
JP6173521B2 (ja) ナルブフィンを含有する製剤及びそれらの使用
KR100882156B1 (ko) 나테글리니드 함유 제제
CN110548026A (zh) 含有葡萄糖激酶激活剂和k-atp通道阻断剂的药物组合及其制备方法和用途
EP2528589A2 (en) Stable efervescent formulations comprising cefaclor
EP3167876B1 (en) Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US20100255099A1 (en) Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
WO2006114042A1 (fr) Application du levo-ornidazole dans la preparation d'un medicament anti-infections par des bacteries anaerobies
KR20190015329A (ko) 다파글리플로진 공결정의 약학 조성물
US20140343076A1 (en) Pharmaceutical compositions of lurasidone
AU2004251439B2 (en) Tablet comprising fluvastatin and carmellose calcium
US20180153835A1 (en) Compositions of diclofenac acid
EP3581180B1 (en) Antimicrobial compositions with effervescent agents
MX2011000349A (es) Composiciones de eprosartan.
RU2611194C2 (ru) Лекарственное средство на основе тетраметилтетраазобициклооктандиона и способ его получения
Khemariya et al. A pioneering approach to enhance dissolution and bioavailability of multiple drugs in a single dosage form: speedy disintegrating tablet of cefpodoxime proxetil and potassium clavulanate
WO2025140767A1 (en) Stable pharmaceutical composition containing dapagliflozin and sitagliptin and process for the preparation thereof
AU2021321092A1 (en) Solid oral composition comprising carbamate compound, and preparation method therefor
EP4633613A1 (en) Pharmaceutical composition comprising rupatadine and montelukast
HK40020067B (en) Antimicrobial compositions with effervescent agents
HK40020067A (en) Antimicrobial compositions with effervescent agents
HK1236006B (en) Antimicrobial compositions with effervescent agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101215

WD01 Invention patent application deemed withdrawn after publication